InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) is a clinical-stage biotechnology company dedicated to developing and commercializing groundbreaking treatments for individuals suffering from spinal cord injuries (SCI). Their pioneering approach centers around the Neuro-Spinal Scaffold™, an investigational bioresorbable polymer scaffold designed to be implanted at the site of injury. The company's mission is to redefine the prognosis for SCI patients, aiming to improve their neurological recovery and overall quality of life. They are focused on advancing their clinical programs and navigating the regulatory pathways to bring their therapies to market.
The headquarters serves as the central hub for InVivo Therapeutics' research and development activities, clinical trial management, corporate strategy, finance, and administrative operations.
Situated in Kendall Square, the facility benefits from proximity to world-class research institutions, a dense network of biotech companies, and a highly skilled talent pool. The building likely offers modern lab and office spaces tailored for life sciences companies.
The work culture at InVivo Therapeutics is likely characterized by a strong scientific focus, a mission-driven approach to patient care, collaboration, and innovation, typical of a clinical-stage biotech company working on challenging medical conditions.
The Cambridge location is highly significant, providing InVivo Therapeutics with strategic advantages in terms of access to cutting-edge research, potential partnerships, clinical expertise, and investment opportunities essential for its growth and development of SCI therapies.
As a clinical-stage company, InVivo Therapeutics's global presence is primarily defined by the locations of its clinical trial sites. While headquartered in the US, their studies may involve research hospitals and medical centers in North America and potentially other regions as their programs advance. Manufacturing of their investigational products and core R&D are likely managed from or through their US base, potentially with global contract research organizations (CROs) and contract manufacturing organizations (CMOs).
One Kendall Square, Building 1400W, Suite 14-103
Cambridge
MA
USA
Address: N/A
Focus is on executing clinical trials which may occur at various medical centers, rather than establishing distinct regional offices for broader commercial or R&D purposes at this stage.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, InVivo Therapeutics' leadership includes:
InVivo Therapeutics has been backed by several prominent investors over the years, including:
In the past 12-18 months, a key executive appointment was Heather Hamel as CFO. Other significant changes are typically announced via press releases or SEC filings.
Discover the tools InVivo Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
InVivo Therapeutics likely uses a common professional email format, typically combining elements of an employee's name with the company domain.
[firstinitial][last]@invivotherapeutics.com
Format
rtoselli@invivotherapeutics.com
Example
80%
Success rate
GlobeNewswire • January 25, 2024
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the pricing of a registered direct offering of 3,125,000 shares of its common stock at a purchase price of $0.80 per share. The gross proceeds from the offering are expected to be approximately $2.5 million, before deducting placement agent fees and other offering expenses....more
GlobeNewswire • November 9, 2023
InVivo Therapeutics reported its financial results for the third quarter ended September 30, 2023, and provided an update on its business operations, including progress on its INSPIRE 2.0 clinical study for acute spinal cord injury....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including InVivo Therapeutics, are just a search away.